Oruka Therapeutics

Today marks the start of Psoriasis Action Month, a time to raise awareness, share stories, and support the more than 8 million people in the U.S. and 125 million worldwide living with psoriasis. At Oruka, we're working to develop new treatments for psoriasis that enable the greatest possible freedom from disease. To us, that means once or twice per year dosing, higher rates of disease clearance, and the potential for off-treatment remission. We stand with the National Psoriasis Foundation and entire psoriasis community. Find tools, resources, and stories that empower those impacted by psoriasis all month long at https://lnkd.in/dJnMgK4 #PsoriasisActionMonth

We are excited to announce that the FDA has cleared Oruka’s IND application for a Phase 2a trial of ORKA-001 (our long-acting anti-IL-23p19 antibody) in moderate-to-severe psoriasis. The study, called EVERLAST-A, has the potential to demonstrate the multiple ways ORKA-001 could redefine the standard of care in psoriasis, including once per year dosing, off-treatment remissions, and higher rates of disease clearance. Additional details on the EVERLAST-A design, as well as interim data from the ORKA-001 Phase 1 study, will be presented at the European Academy of Dermatology and Venereology (EADV) Congress in September. Read the full press release here: https://lnkd.in/ehKsVKVU

We're thrilled to announce the promotion of Laura Sandler to Chief Operating Officer. Since joining Oruka as SVP of Operations in 2024, Laura has been a driving force behind the rapid advancement of our pipeline into the clinic, bringing both speed and precision to everything she leads. As COO, she will continue to lead execution across our programs as we pursue our mission to offer patients suffering from chronic skin conditions the greatest possible freedom from disease. Read the full news here: https://lnkd.in/eTdxNRcw

We're thrilled to announce the promotion of Laura Sandler to Chief Operating Officer. Since joining Oruka as SVP of Operations in 2024, Laura has been a driving force behind the rapid advancement of our pipeline into the clinic, bringing both speed and precision to everything she leads. As COO, she will continue to lead execution across our programs as we pursue our mission to offer patients suffering from chronic skin conditions the greatest possible freedom from disease. Read the full news here: https://lnkd.in/eTdxNRcw

We’re excited to announce that the first participants have been dosed in a Phase 1 trial of ORKA-002, our novel, half-life extended monoclonal antibody targeting IL-17A/F. Read the full press release here: https://lnkd.in/e9KqHahh.

We’re excited to announce that the first participants have been dosed in a Phase 1 trial of ORKA-002, our novel, half-life extended monoclonal antibody targeting IL-17A/F. Read the full press release here: https://lnkd.in/e9KqHahh.

Today, we reported Q1 2025 financial results and updates from across our pipeline. We have continued to make rapid progress to advance ORKA-001 and ORKA-002, and as we ramp up preparations for our first psoriasis studies, we're energized by the reception from physicians, who clearly see the potential to advance the treatment paradigm in this important disease. Read more here: https://lnkd.in/eNmgG5Gv

As we embark on Psoriatic Arthritis (PsA) Action Month, our thoughts are with everyone touched by PsA. While PsA brings its share of challenges, it also showcases the strength and resilience of a remarkable community. At Oruka, we're honored to play a part in supporting this community by developing novel treatments that hold the promise of greater freedom from disease. #PsAActionMonth

We’re excited to present new preclinical data on ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F, at the AAD Annual Meeting in Orlando. The data show that ORKA-002 has a >3-fold longer half-life in NHPs than bimekizumab, while binding to a nearly identical epitope with similar potency. We expect to initiate a Phase 1 study of ORKA-002 in Q3 2025. For more information, you can read the full news release here: https://lnkd.in/eZV9F4gw, and view the poster on our website here: https://lnkd.in/ewHG6ACg.

Today, we reported Q4 and full-year 2024 financial results and updates from across our pipeline. We made tremendous progress in our first year as a company, including our successful public debut and advancing ORKA-001 into the clinic. Looking forward, we expect to deliver a clinical catalyst every six months, which could progressively establish ORKA-001 and ORKA-002 as the best treatment options in psoriatic disease. Read more here: https://lnkd.in/eRR3eexy